Cancer Biology 2025
Last updated
We are pleased to present this special collection of articles recently published in LSA highlighting some of the latest advances in cancer biology. Articles featured in the collection were published within the past 12 months and include original findings on metastasis modeling, NUT carcinoma and immunotherapy.
We hope you enjoy reading this collection, and we invite you to follow LSA on X/Twitter (@LSAjournal) and Bluesky (@LSAjournal.org). Learn more about submitting your research.
Image © 2024 Anandi et al.
Observing early metastases in vivo is virtually impossible, and most culture systems lack the conditions that tumor cells encounter early in the metastatic process. We thus developed the 3MIC—an ex vivo cell culture system—allowing the direct observation of nascent metastases.
A shift of arginine metabolism from polyamine synthesis to nitric oxide synthesis induces reprogramming of macrophages from pro-tumor M2 to anti-tumor M1 types.
The authors present a novel automated approach for the identification of blasts and their developmental stage in a longitudinal pediatric acute myeloid leukemia (AML) cohort. KMT2A-rearranged AMLs show unstable immunophenotype, with most patients presenting a more differentiated phenotype at relapse.
This work presents a novel Consensus Molecular Subtypes (CMS) classifier for colorectal cancer (CRC), optimized for RNA-sequencing data stemming from degraded RNA of clinical formalin-fixed paraffin-embedded (FFPE) tissue samples (the CMSFFPE classifier).
This study developed the first GEMM for NUT carcinoma to syntenically recapitulate the t(15;19) chromosome translocation in humans, serving as a critical preclinical model for the disease.
Crosstalk between bone metastatic cancer cells and sensory nerves has not yet been fully elucidated. We demonstrate the involvement of CGRP-expressing sensory nerves in bone metastatic progression and identify the CGRP/CRLR axis as a potential therapeutic target for bone metastasis.
Specific mitochondrial proteins are associated with resistance to treatments targeting polo-like kinase 1 activity or expression in melanoma. Resistant cells are less apoptotic and trigger a transcriptional program of dedifferentiation and a pro-inflammatory phenotype.
Colorectal cancers co-express the αDβ1 integrin and hemoglobin δ, and down-regulation of either protein in hypoxia inhibited oxygen uptake and cell proliferation.
Chromatin-centred proteomics study in stem cells with different DNMT expression levels and activities reveals that decitabine invokes different DNA damage responses depending on the amount of the induced DNA-DNMT crosslinks.
A triple osimertinib/calcineurin A/trametinib combination of treatment overcomes acquired resistance to EGFR TKI in EGFR-mutant lung adenocarcinoma cells that overexpress PPP3CB.
